Rapid Pharmacokinetics Suprane delivers the lowest fat/blood distribution coefficient and lowest accumulation in adipose tissue among current potent inhalational anaesthetics.3.4

Low accumulation, even with long surgeries3

100

80

60

40

20

00 50 100 150 200 250 300 350

Duration of anaesthesia (minutes)

90%

was

hout

tim

e (m

inut

es)

Fig. modified based on Bailey JM 1997.

Isoflurane

Sevoflurane

Suprane®

Rapid uptake and clearance at the site of action4

1.4

0.65

0.45

1.40

1.20

1.00

0.80

0.60

0.40

0.20

0.00

Blood/gas

Dist

ribut

ion

coef

ficie

nt

Dist

ribut

ion

coef

ficie

nt

50 52

29

60

50

40

30

20

10

0

Fat/blood

Isoflurane

Sevoflurane

Suprane®

The Suprane advantage in Obese Patients:

Alert, cooperative

patients post-surgery.

Study or subgroup Mean difference IV, sample, 95% CI

1.1.1 Time to eye openingArain 0.50 (–1.44; –2.44)

De Baerdemaeker –2.14 (–3.59; –0.69)Kaur –4.77 (–7.47; –2.07)La Colla –4.50 (–5.99; –3.01)Strum –8.60 (–12.44; –4.76)Vallejo –1.00 (–2.90; –0.90)Subtotal (95% CI) –3.09 (–5.13; –1.06)Heterogeneity: tau = 5.15; chi = 31.02; df = 5 (p <0.00001); I = 84%. Test for overall effect: Z = 2.98 (p = 0.003).

1.1.2 Time to extubationArain 0.40 (–1.68; 2.48)De Baerdemaeker –2.03 (–3.59; –0.47)La Colla –7.00 (–7.94; –6.06)Strum –11.30 (–16.95; –5.65)Vallejo –1.06 (–4.32; 1.12)Subtotal (95% CI) –3.88 (–7.42; –0.34)Heterogeneity: tau = 14.30; chi = 67.33; df = 4 (p <0.00001); I = 94%. Test for overall effect: Z = 2.154 (p = 0.03).

1.1.3 Time to state nameDe Baerdemaeker –2.40 (–3.92; –0.88)Kaur –6.24 (–10.21; –2.276)La Colla –7.00 (–8.04; –5.96)Strum –13.70 (–17.04; –10.36)Subtotal (95% CI) –7.15 (–11.00; –3.30)Heterogeneity: tau = 13.62; chi = 45.64; df = 3 (p <0.00001); I = 93%. Test for overall effect: Z = 3.64 (p = 0.0003). Test for subgroup differences: chi = 19.61; df = 3 (p = 0.0002); I = 84.7% Fig. modified based on Liu et al. 2015; 264 patients in 6 selection studies. * Standard deviation

–20 –10 0 10 20Favors Desflurane Favors Sevoflurane

Mean difference IV, sample, 95% CI

Meta-analysis of 11 randomized clinical trials with morbidly obese patientsSuprane vs. Sevoflurane

Suprane was shown to deliver significantly faster recovery and rapid return of protective breathing reflexes as compared to sevoflurane–independent of BMI.5

Prospective randomized study with 120 patients distributed into 3 BMI groups. Objective was to drink 20 ml of water 2 minutes after initial response to command without choking.5

BMI (Body Mass Index), duration of anaesthesia, and protective breathing reflexes5

% o

f pat

ient

s w

ho c

an s

wal

low

100

80

60

40

20

0

Minutes after reaction to a command

Sevoflurane Desflurane

BMI ≥30

BMI ≥30

* p <0.0005 ** p <0.00001 Fig. modified based on McKay et al. 2010.

*

**

BMI 18–24

BMI 18–29

BMI 25–29

0 2 6 10 140 2 6 10 14

Rapid RecoveryMeta-analysis indicated that recovery was significantly faster in the Suprane (desflurane) groups than in the sevoflurane, isoflurane, and propofol groups in obese adult patients who underwent major abdominal surgery.6

A possible Suprane advantage in obese patients: Less risk of critical respiratory events during early recovery from anaesthesia.5

Globally, there are more than 1 billion overweight adults, at least 300 million of them obese.1 This has led to an increase in obese surgical patients who require anaesthesia.2

SUPRANE (DESFLURANE) MAY DELIVER SIGNIFICANT ADVANTAGE IN OVERWEIGHT AND OBESE PATIENTS

Baxter AG, Scienti�c o�cePlot. 233 Second Sector City Center5th Settlement, New Cairo, O� Road 90,Cairo, EgyptT: +202 261 42 300www.baxter.com

SUPRANE, registration number: 19423 / 2007(SPC) REVISED version Date: 03 / 2019.EGYZ/12/ 20 - 0015